|
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. |
|
|
Consulting or Advisory Role - bioTheranostics; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Merck (Inst); Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals |
Research Funding - bioTheranostics |
|
|
Research Funding - Ambryx (Inst); Amgen (Inst); Bayer (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Medivation (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); sanofi (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Lilly; Novartis; OBI Pharma |
|
|
Honoraria - Pfizer; Pfizer |
Consulting or Advisory Role - Calithera Biosciences; Context Therapeutics; Novartis; Pfizer (I) |
Research Funding - Bayer (Inst); Calithera Biosciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Millennium (Inst); Pfizer (Inst); Veridex (Inst); Wyeth (Inst) |
Travel, Accommodations, Expenses - Calithera Biosciences; Novartis; Pfizer; Pfizer; Pfizer |
|
|
Consulting or Advisory Role - Novartis |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - Immunomedics (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst) |
|
|
Consulting or Advisory Role - Biotheranostics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo/Lilly (Inst); Eisai (Inst); Genentech/Roche (Inst); NanoString Technologies (Inst); Novartis (Inst) |
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Novartis |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); InventisBio (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Novartis |
|
|
Consulting or Advisory Role - MD Anderson Physician’s Network; Pfizer |
|
|
Honoraria - bioTheranostics |
Consulting or Advisory Role - bioTheranostics |
Research Funding - bioTheranostics (Inst) |
|
|
Employment - Northwest Medical Specialties; University of Washington (I) |
Leadership - Northwest Medical Specialties |
Stock and Other Ownership Interests - Northwest Medical Specialties |
Honoraria - American Journal of Managed Care; Cardinal Health; Novartis; Puma Biotechnology |
Research Funding - Northwest Medical Specialties |
Expert Testimony - Northwest Medical Specialties |
Travel, Accommodations, Expenses - Northwest Medical Specialties |
Other Relationship - All4Cure (I); Northwest Medical Specialties; Quality Cancer Care Alliance |
|
|
Honoraria - Boehringer Ingelheim; Lilly; Novartis |
Consulting or Advisory Role - Amgen; G1 Therapeutics; Genentech/Roche; Merck |
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Lilly; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Biovica; Lilly; Merck; Novartis; Pfizer; Pfizer; Puma Biotechnology; Syndax; Tempus |
Research Funding - Eisai (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Novartis; pfizer; Syndax |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
|
|
Honoraria - Novartis; Pfizer (I) |
Research Funding - Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Genentech (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Novartis; Pfizer (I) |